Skip to Content

'
Felipe Samaniego, M. D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M.D. Anderson Cancer Center
7455 Fannin St
Unit 903
Houston, TX 77054
Phone: 713-563-1509
Fax: 713-563-7314

Education & Training

Degree-Granting Education

1983 Harvard Medical School, Boston, MA, MD, Medicine
1983 Harvard School of Public Health, Boston, MA, MPH, Health Services
1978 New Mexico State University, Las Cruces, NM, BS, Biology

Postgraduate Training

1990-1995 RESEARCH FELLOW, Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, NIH, Bethesda, MD
1986-1990 CLINICAL FELLOW, Hematology-Oncology, Hematology-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
1984-1986 RESIDENT, University of Colorado Health Sciences Center, Denver, CO
1983-1984 INTERN, University of Colorado Health Sciences Center, Denver, CO

Board Certifications

1989 American Board of Medical Oncology
1986 American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2003-2006
Assistant Professor, Human Virology, Institute of Human Virology, University of Maryland Medical Center, Maryland, MD, 1996-1999

Honors and Awards

2002 AACR-MICR Council Member, AACR-MICR
1989 Daland Fellowship, Alternate Fellow
1989 Robert Wood Johnson Foundation Fellow

Selected Publications

Abstracts
1. Fowler, Mclaughlin, Kwak, Fanale, Hagemeister, Fayad, Pro, Samaniego. Lenalidomide and rituximab for untreated indolent B cell non-Hodgkins lymphoma. J Clin Oncol 27(8548), 12/2009.
2. Berkova Z, Garcia M, Wang S, Wise JF, Tao RH, Danulik U, Samaniego F. Direct Inhibition of Fas Activation by CD74. Proc Am Soc Hem (#24309), 11/2009.
3. Tao RH, Berkova Z, Samaniego F, et al. Promyelocytic leukemia-retinoic acid receptor a binds and prevents activation of the Fas receptor and suppresses Fas-mediated apoptosis. Proc Am Soc Hem (#22629), 11/2009.
4. Fowler N, McLaughlin P, Samaniego F. A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin’s lymphoma. Proc Am Soc Hem (#22629), 2009.
5. Fanale M, Neelapu S, Faya L, Pro B, Sergent C, White S, Samaniego F. A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma, 2009.
6. Fanale M, Fayad L, McLaughlin P, Pro B, Sergent C, Hagemeister F, Romaguera J, Samaniego F, Rodriguez A, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Results of Long Follow up and Comparison to Institutional Historical Data, 2009.
7. Vamsidhar V, Li L, Phillips J, Fuloria J, Rodwig FR, Cole J, Samaniego F, Prakash O. Preclinical Evaluation of Lyn Kinase Inhibition for the Treatment of B Cell Chronic Lymphocytic Leukemia (B-CLL), 2009.
8. Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Sha J, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome, 2009.
9. Saroj V, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera J,. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Proc Am Soc, 2009.
10. Maeng H, Berkova Z, Wang S, Wang S, Prakash O, Yi Q, Samaniego F. Human herpesvirus 8 protein K1 interferes with Fas-mediated apoptosis and stimulates clonal growth and lymphoid hyperplasia. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research(A2712), 2008.

Last updated: 3/7/2013